
Anika Therapeutics (ANIK) Stock Forecast & Price Target
Anika Therapeutics (ANIK) Analyst Ratings
Bulls say
Anika Therapeutics Inc has demonstrated robust revenue growth within its product lines, particularly with the Integrity patch, which is projected to contribute to more than 100% growth in revenue for 2025 compared to 2024. The company reported a 41% increase in its regenerative solutions business in the latest quarter and a 21% growth in international osteoarthritis pain revenue, indicating strong demand in both domestic and international markets. Furthermore, the significant 13% increase in overseas osteoarthritis pain revenue in Q1 highlights the company's successful expansion efforts and solidifies its position in the orthopedic medicines sector.
Bears say
Anika Therapeutics reported a 5.9% revenue decline to $27.8 million, alongside a recurring 8.2% decrease in revenues on a year-over-year basis, indicating persistent top-line challenges exacerbated by recent divestitures. The company also experienced production yield issues that negatively impacted gross margins, resulting in a gross margin of 56%, which fell short of the estimated 58%. Furthermore, the international revenue from osteoarthritis pain management experienced a significant 10% decrease, highlighting ongoing operational struggles that contribute to a negative outlook for the company's financial health.
This aggregate rating is based on analysts' research of Anika Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Anika Therapeutics (ANIK) Analyst Forecast & Price Prediction
Start investing in Anika Therapeutics (ANIK)
Order type
Buy in
Order amount
Est. shares
0 shares